Evolution of the Average Target: Genmab A/S

Data source: Genmab A/S(GMAB)

Evolution of the Target Price: Genmab A/S

Data source: Genmab A/S(GMAB)

Changes in Analyst Recommendations: Genmab A/S

Data source: Genmab A/S(GMAB)
43a5.o93tuVWrSQncptqzorlfJfcm2w9NRa1Ruxvndhcb6WE.-bGv_Cb5FmGP_J7b7uZyTZtVtVwkdvow_k-GNVgjvAbzr4nUFN0KX5LCnw~0411ad8569b3079f1866a90e7079b31c
08/09 Barclays raises Genmab price target to 2,900 Danish kroner (2,500), reiterates overweight - BN FW
03/09 Handelsbanken Adds Xvivo and Vimian as Sector Favorites, Drops Danish Duo FW
01/09 Deutsche Bank raises price target for Genmab to 2,500 Danish kroner, reiterates buy FW
31/08 Deutsche Bank raises Genmab price target to 2,500 Danish kroner (2,250), reiterates buy FW
20/08 Cancer vaccines finally garner the spotlight Alphavalue
20/08 AlphaValue/Baader Europe Downgrades Genmab to Add, Trims PT MT
12/08 BNP Paribas Initiates Genmab at Outperform, With $40 Price Target MT
07/08 Genmab: Q2 beat reinforces the investment story; diversification efforts remain on course Alphavalue
07/08 UBS raises Genmab price target to 2,700 Danish kroner (2,600), reiterates buy FW
07/08 Analysts upbeat on Genmab after strong Q2 FW
07/08 Goldman Sachs raises Genmab target price to 2,400 Danish kroner (2,350), reiterates buy - BN FW
07/08 TD Cowen raises Genmab price target to 2,892 Danish kroner (2,851), reiterates buy FW
07/08 Jyske Bank raises Genmab target price to 2 350 Danish kroner (2 300), reiterates buy - BN FW
07/08 Nordea raises its target price for Genmab to 2,083 Danish kroner (2,015), reiterates buy FW
22/07 TD Cowen Upgrades Genmab to Buy Rating, Boosts PT MT
22/07 TD Cowen Upgrades Genmab to Buy From Hold, Raises Price Target to $43 From $32 MT
22/07 TD Cowen upgrades Genmab to buy (hold) - BN FW
21/07 Goldman Sachs raises Genmab price target to 2,350 Danish kroner (2,300), reiterates buy - BN FW
15/07 Where would AI lead Pharma in the long run? Alphavalue
07/07 Genmab rebounds on a European Commission decision Zonebourse
06/07 BNP Paribas raises the target price for Genmab to 2,500 Danish kroner (2,400), reiterates outperform - BN FW
24/06 AlphaValue/Baader Europe Reduces EPS Estimates for Genmab on Merger Financing Costs MT
23/06 Genmab: Financing weighs now, pipeline pays later Alphavalue
18/05 Genmab Maintained at Buy as BofA Notes Upcoming Key Catalysts MT
12/05 Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target FW

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - - -
+23.69%
+18.14%
+54.69%
+23.66%
+23.2%
+17.29%
+9.16%
+32.94%
+66.45%
Average +29.91%
Weighted average by Cap. +26.95%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
2,092.00DKK
Average target price
2,453.79DKK
Spread / Average Target
+17.29%
High Price Target
2,930.00DKK
Spread / Highest target
+40.06%
Low Price Target
1,400.00DKK
Spread / Lowest Target
-33.08%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!